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Abstract
Macrophage migration inhibitory factor (MIF) mediates pain although the
mechanisms are not well understood. Urothelial activation of protease acti-
vated receptor 4 (PAR4) results in urothelial MIF release, urothelial high
mobility group box 1 (HMGB1) release and bladder pain in mice without
bladder inflammation. All three effects are prevented by MIF inhibition while
intravesical disulfide HMGB1 alone can induce bladder pain. This study uti-
lizes genetic MIF deletion to determine whether MIF mediates PAR4-induced
bladder pain and is upstream of HMGB1-induced bladder pain. Wild type
(C57/BL6) and MIF knockout (KO) mice were treated with intravesical PAR4
activating peptide or disulfide HMGB1 and tested for abdominal mechanical
hypersensitivity at baseline (before treatment) and 24 h after injection. Mic-
turition parameters and bladder histology were examined after behavioral test.
Real-time PCR and western blotting measured HMGB1 mRNA and protein
levels in the bladders of na€ıve wild type and MIF KO mice, while immunoflu-
orescence measured HMGB1 protein levels in the urothelium of both strains.
Intravesical PAR4 activation resulted in abdominal mechanical hypersensitivity
in wild-type mice but not MIF KO mice. Intravesical disulfide HMGB1
induced abdominal mechanical hypersensitivity in both strains. Neither treat-
ment resulted in significant changes in micturition or bladder histology in
either strain. HMGB1 mRNA and protein levels were higher in MIF KO
mouse bladders and the urothelium of MIF KO bladder had greater
immunostaining than the wild-type strain. MIF is a pivotal molecule mediat-
ing PAR4-induced bladder pain and regulating urothelial HMGB1 production
and release to elicit bladder pain.
Introduction
Macrophage migration inhibitory factor (MIF) is a cyto-
kine that is pre-formed in various types of cells and
stored in vesicles to be released upon appropriate stimuli
(Lolis and Bucala 2003). MIF is known as a key player in
innate and adaptive immune responses (Flaster et al.
2007). Recent evidence indicates that MIF is involved in
nociception, either by mediating pain induced by inflam-
mation or nerve injury (Morand et al. 2002; Aloisi et al.
2005; Ellis et al. 2014) or by eliciting pain directly
(Alexander et al. 2012; Lerch et al. 2014).
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MIF is expressed in central nervous system cells (in-
cluding neurons and glial cells) and also expressed in
peripheral tissues such as macrophages, choroid plexus,
anterior pituitary, gastric, colonic, and urinary epithelium
(Meyer-Siegler 2001; Lue et al. 2002; Vera and Meyer-
Siegler 2003). MIF release was observed from bladder
urothelium and peripheral as well as central nervous sys-
tem in a different inflammatory model of cystitis in
rodents (Vera and Meyer-Siegler 2003; Meyer-Siegler and
Vera 2004; Vera et al. 2010).
Animal models of painful bladder syndrome/interstitial
cystitis (PBS/IC) usually employ chemical-initiated blad-
der injury or inflammation (Saban et al. 2001; Westropp
and Buffington 2002; Cruz et al. 2005). We recently
reported that activation of urothelial protease activated
receptor 4 (PAR4) receptors results in urothelial MIF
release, urothelial high mobility group box 1 (HMGB1)
release and abdominal mechanical hypersensitivity (indi-
rect index of bladder pain) in mice without resulting in
other inflammatory changes or altering voiding behavior.
These three effects were blocked by a MIF antagonist sug-
gesting that MIF mediated HMGB1 release and abdomi-
nal hypersensitivity (Kouzoukas et al. 2015).
HMGB1, a ubiquitous and abundant non-histone
nuclear chromatin-binding protein, is actively secreted in
response to inflammatory signals and is recognized as
mediating pain (Agalave and Svensson 2015). In fact,
intravesical administration of HMGB1 (in its disulfide
form, dsHMGB1) induced abdominal mechanical hyper-
sensitivity through urothelial Toll-like receptor 4 (TLR4)
without causing bladder inflammation or micturition
changes (Ma et al. 2017).
We hypothesized that MIF is a pivotal molecule in
PAR4-activation induced bladder pain and that MIF medi-
ates urothelial HMGB1 release to bind to urothelial
HMGB1 receptors resulting in bladder pain. However, it is
not clear if MIF deletion will break the signaling pathway
in this PAR4 activation model of bladder pain. This study
utilized global MIF knockout (KO) to test this hypothesis
and investigate more precisely the role of MIF in PAR4-
induced bladder pain and urothelial HMGB1 regulation.
Material and Methods
Animals
All animal experiments were approved by the Lexington
Veterans Affairs Medical Center Institutional Animal Care
and Use Committee (VER-11-016-HAF) and performed
according to the guidelines of the National Institutes of
Health. MIF knockout mice were obtained from Yale
University and bred in our animal facility (Fingerle-Row-
son et al., 2003) and wild-type C57/BL6 mice were
purchased from Jackson Laboratory (Jackson Laboratory,
Bar Harbor, ME).
Abdominal mechanical hypersensitivity test
Abdominal mechanical hypersensitivity was tested in mice
as previously described (Kouzoukas et al. 2015). Briefly,
von Frey filaments of ascending bending force (0.008,
0.02 0.04, 0.07 g) were pressed to the lower abdominal
region in trials of 10 before (baseline) and 24 h after
intravesical instillation of either PAR4 scramble (H-Tyr-
Ala-Pro-Gly-Lys-Phe-NH2, PAR-3933-PI) or PAR4-acti-
vating peptide (PAR4-AP, a short synthetic peptide that
stimulates PAR4 in a protease-independent manner, H-
Ala-Tyr-Pro-Gly-Lys-Phe-NH2, PAR-3674-PI, Peptides
International, Louisville, KY) (100 lmol/L/150 lL PBS)
or dsHMGB1 (10 lg/150 lL PBS, HM-121, HMGBion-
tech, Italy) to detect referred bladder pain. Positive
response was defined as any one of three behaviors: (1)
licking the abdomen, (2) flinching/jumping, or (3) abdo-
men withdrawal. Mice responding more than 30% to the
weakest filament (0.008 g) during baseline testing were
excluded from the study.
Voided stain on paper (VSOP)
Micturition volume and frequency were measured in
awake mice as previously described (Sugino et al. 2008;
Ma et al. 2017). Briefly, mice were gavaged with water
(50 ll/g body weight) to induce diuresis, and then placed
in a plastic enclosure. Mice were free to move and filter
paper was placed under the animal to collect urine during
a 2 h observation period. Micturition volumes were
determined by linear regression using a set of known vol-
umes. Micturition frequency was defined as total number
of micturitions in two hours.
Histology and immunohistochemistry
Bladder paraffin sections (5 lm) were processed for rou-
tine hematoxylin and eosin (H&E) staining. H&E stained
sections were evaluated by a pathologist blinded to the
experimental treatment and scored for edema and inflam-
mation according to the following scale: 0, No edema and
no infiltrating cells; 1, Mild submucosal edema and no
inflammatory cells; 2, Moderate edema and several
inflammatory cells; 3, Frank edema, vascular congestion
and many inflammatory cells.
For immunohistochemistry, batch-stained paraffin sec-
tions (N = 6/group) were blocked (5% goat serum, 0.2%
Triton X-100 in PBS, 30 min at room temp.), then incu-
bated overnight at 4°C with rabbit polyclonal anti-
HMGB1 antibody (1:100; ab18256; Abcam, Cambridge,
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MA). Immunoreactivity was detected with goat anti-rab-
bit TRITC-labeled secondary antibody (1:100 in PBS with
1% goat serum, 0.2% Triton X-100; 1 h at room temp.;
Jackson ImmunoResearch, Inc., West Grove, PA) before
cover-slipping (Vectashield, Vector Laboratories, Burlin-
game, CA). Computer-assisted densitometry of HMGB1
immunostaining intensity was performed on images cap-
tured using a LEICA DMI4000B microscope equipped
with the LAS V4 program and ImageJ (NIH, Bethesda,
MD).
Western blotting
Proteins extracted from bladder tissue of na€ıve wild type
and MIF knockout mice were separated using a 4–15%
Mini-PROTEAN TGX precast polyacrylamide gel (Bio-
Rad, Hercules, CA). After electrophoresis, separated pro-
teins were transferred to a polyvinylidene difluoride
membrane. HMGB1 protein bands were visualized using
a rabbit polyclonal primary antibody (ab18256; Abcam,
Cambridge, MA; 1:4000), along with GAPDH as an inter-
nal control (A00915, GenScript, Piscataway, NJ; 1:2500), a
biotinylated anti-rabbit secondary antibody (Vector Labs,
Burlingame, CA; 1:400), streptavidin-HRP conjugates and
chemiluminescent substrate (Pierce, Rockford, IL). Band
densitometry was performed using ImageJ (NIH,
Bethesda, MD).
Real-time PCR
Total RNA was extracted from wild type and MIF
knockout mouse bladder tissue through Trizol
(15596026, ThermoFisher Scientific, Grand Island, NY),
DNA removed by DNase, and reversed transcribed to
cDNA (A3500, Promega, Madison, WI). SYBR green
(4472903, ThermoFisher Scientific, Grand Island, NY)
was utilized with primers (HMGB1, PPM05059F; Rn18s,
PPM72041A, Qiagen, Germantown, MD) to quantified
level of mRNA in bladder tissue from wild type and
MIF knockout mice. 18S rRNA was used as the internal
control.
Statistical analyses
Changes in positive response frequency (%) to von Frey
stimulation at baseline and 24 h after treatment were
evaluated using a within subject two-way (Time x Fila-
ment Strength) ANOVA. When the Time factor (pre vs.
post) was significant, differences at each filament strength
were compared (pre vs. post) using t-tests with a multiple
comparison adjustment (Holm-Sidak). Micturition
parameters (volume; frequency) were analyzed using a
two-way ANOVA (treatment vs. strain).
Results
Lack of response to intravesical PAR4-AP in
MIF KO mice
PAR4-AP was administered intravesically to wild type and
MIF knockout mice after baseline von Frey measurement.
Twenty-four hours after injection, abdominal mechanical
sensitivity to von Frey filaments was tested again. In wild-
type mice, PAR4-AP induced increased number of
responses to von Frey filaments on abdominal/perianal
area. Wild-type mice showed significant increases in per-
centage of responses to all strength of filaments (0.008,
0.02, 0.04, and 0.07 g) compared to baseline (P < 0.01 or
0.001 on all comparison between before and after PAR4-
AP injection of all four filaments, n = 5, Fig. 1B). PAR4
scramble injection did not develop any hypersensitivity
on abdomen in wild-type mice (n = 6, Fig. 1A). However,
PAR4-AP did not cause any abdominal mechanical hyper-
sensitivity in MIF knockout mice. For each filament, there
was no increase in percent response to abdominal
mechanical stimuli at 24 h after PAR4-AP injection com-
pared to baseline (P > 0.05 on each filament along each
time point, n = 4, Fig. 1D). PAR4 scramble as control
also did not cause any behavioral changes in MIF knock-
out mice (n = 3, Fig. 1C).
Intravesical dsHMGB1 induced abdominal
mechanical hypersensitivity in MIF KO mice
DsHMGB1 was administered intravesically to wild type and
MIF knockout mice after baseline measurement. Twenty-
four hours after injection, abdominal mechanical sensitivity
to von Frey filaments was tested again. In wild-type mice,
dsHMGB1 induced increased number of responses to von
Frey filaments on abdominal/perianal area. Wild-type mice
showed significant increases in percentage of responses to
all strength of filaments (0.008, 0.02, 0.04, and 0.07 g) com-
pared to baseline (P < 0.05 or 0.01 on all comparison
between before and after dsHMGB1 injection of all four fil-
aments, n = 6, Fig. 2B). Vehicle (PBS) injection did not
develop any abdominal hypersensitivity in wild-type mice
(n = 5, Fig. 2A). Similarly, dsHMGB1 caused abdominal
mechanical hypersensitivity in MIF knockout mice to von
Frey filaments on abdominal/perianal area by increasing
percentage of responses to all strength of filaments (0.008,
0.02, 0.04, and 0.07 g) compared to baseline (P < 0.01 or
0.001 on all comparison between before and after
dsHMGB1 injection of all four filaments, n = 6, Fig. 2D).
There was no increase in percent response to abdominal
mechanical stimuli at 24 h after vehicle injection compared
to baseline (P > 0.05 on each filament along each time
point) (n = 5, Fig. 2C).
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Micturition changes after intravesical PAR4-
AP or dsHMGB1 injection
Micturition parameters were recorded 24 h after PAR4-
AP or dsHMGB1 injection. PAR4-AP did not result in
statistically significant changes in urine volume (in lL)
or frequency when compared to scrambled peptide
(control) in either of the mouse strains (Table 1A).
Moreover, intravesical dsHMGB1 treatment produced
no statistically significant changes on micturition vol-
ume or frequency when compared to vehicle treatment
in either strain (Table 1B). Micturition volume was sig-
nificantly larger in MIF knockout mice receiving control
treatment (632  101 for PAR4 scramble and
675  66.9 for PBS; P < 0.01; Table 1) compared to
wild-type mice receiving control treatments (257  11.4
for PAR4 scramble and 301  35.2 for PBS; Table 1).
Similarly, micturition frequency was lower in MIF
knockout mice (1.0  0.0 for PAR4 scramble and
1.2  0.2 for PBS; P < 0.01; Table 1) compared to
wild-type mice (3.3  0.3 for PAR4 scramble and
3.0  0.3 for PBS; Table 1).
Histology after intravesical PAR4-AP or
dsHMGB1 injection
H&E stained bladder sections from wild-type and MIF
knockout mice that received intravesical PAR4-AP or
dsHMGB1 were examined by a pathologist blinded to the
treatment and scored for inflammation and edema changes.
Neither PAR4-AP (Figure S1) nor dsHMGB1 (Figure S2)
treatment produce statistically significant changes in
inflammation or edema in either of the strains (Table 2).
Increases in HMGB1 mRNA and protein
levels in the bladder of MIF KO mice
Bladder levels of HMGB1 mRNA and protein were
examined in both wild type and MIF knockout mice.
Real-time PCR result showed that basal level of HMGB1
Figure 1. Abdominal mechanical sensitivity after PAR4 in WT and MIF KO mice. PAR4 activating peptide or PAR4 scramble was intravesically
injected into WT and MIF knockout mice. Abdominal mechanical sensitivity was measured 24 h after instillation. (A) PAR4 scramble did not
induce mechanical response change in WT mice (n = 6). (B) PAR4 significantly increased number of responses to abdominal mechanical
stimulation in WT mice (n = 5). Neither PAR4 scramble (n = 3) (C) nor PAR4 (n = 4) (D) caused abdominal mechanical hypersensitivity in MIF
knockout mice. **P < 0.01; ***P < 0.001.
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mRNA in MIF knockout mice is 16.4 times of that in
wild-type mice when normalized to 18S rRNA
(P < 0.05). Protein levels of bladder HMGB1 were tested
by both western blot and immunofluorescence. Western
blots showed higher levels of HMGB1 (normalized to
GAPDH) intensity in bladders from MIF knockout mice
than from wild-type mice (P < 0.05;) (Fig. 3A, B).
HMGB1 immunofluorescence (Fig. 4) showed stronger
fluorescence in bladder urothelium in MIF knockout
mice (Fig. 4B) than that in wild-type mice (Fig. 4A).
Densitometry showed that this difference was statistically
significant (P < 0.05) (Fig. 4C).
Figure 2. Abdominal mechanical hypersensitivity after dsHMGB1 in WT and MIF KO mice. DsHMGB1 or vehicle (PBS) was intravesically injected
into WT and MIF knockout mice. Abdominal mechanical sensitivity was measured 24 h after instillation. (A) PBS did not induce mechanical
response change in WT mice (n = 5). (B) DsHMGB1 significantly increased number of responses to abdominal mechanical stimulation in WT
mice (n = 6). (C) PBS did not cause mechanical stimulation response change in MIF knockout mice (n = 5). (D) DsHMGB1 significantly increased
number of responses to abdominal mechanical stimulation in MIF knockout mice (n = 6). *P < 0.05; **P < 0.01; ***P < 0.001.
Table 1. Micturition after intravesical administration in WT and MIF KO mice.
WT MIF KO
Volume (lL) Frequency Volume (lL) Frequency
(A)
PAR4 scramble 257  11.4 3.3  0.3 (n = 6) 632  101** 1.0  0.0** (n = 3)
PAR4 235  24.3 4.6  0.9 (n = 5) 417  84.9 1.8  0.5 (n = 4)
(B)
PBS 301  35.2 3.0  0.3 (n = 5) 675  66.9** 1.2  0.2** (n = 5)
dsHMGB1 265  25.5 4.0  1.0 (n = 6) 485  97.3 1.8  0.4 (n = 6)
(A) **P < 0.01 compared to WT PAR4 scramble (B) **P < 0.01 compared to WT PBS; value: mean  SE. Bold indicates significance value.
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Discussion
The present results clearly demonstrate that MIF is a sig-
naling molecule mediating bladder pain. Intravesical
PAR4 activation resulted in abdominal mechanical hyper-
sensitivity in wild-type mice, in agreement with our ear-
lier reports (Kouzoukas et al. 2015, 2016), but not in MIF
knockout mice. Moreover, dsHMGB1 induced abdominal
mechanical hypersensitivity in both wild-type and MIF
knockout mice indicating that HMGB1 is downstream of
MIF.
Histological scoring showed no significant changes in
the bladder 24 h after either PAR4 or dsHMGB1 instilla-
tion, as we reported earlier (Kouzoukas et al. 2015, 2016;
Ma et al. 2017). H&E staining showed no infiltrating cells
with minimal to mild bladder edema and stromal reactive
changes in some mice (reactive submucosal fibrosis with
lamina propria expansion).
Table 2. Histology after intravesical administration in WT and MIF KO mice.
WT MIF KO
Inflammation Edema Inflammation Edema
(A)
PAR4 scramble 0.0  0.0 0.0  0.0 (n = 6) 0.7  0.3 0.3  0.3 (n = 3)
PAR4 0.0  0.0 0.0  0.0 (n = 5) 0.8  0.5 0.8  0.5 (n = 4)
(B)
PBS 1.0  0.6 1.0  0.6 (n = 5) 0.8  0.2 1.2  0.4 (n = 5)
dsHMGB1 0.5  0.5 1.0  0.5 (n = 6) 0.7  0.3 1.3  0.4 (n = 6)
value: mean  SE.
Figure 3. Elevated HMGB1 in MIF KO by western blot. HMGB1 protein was measured from bladder extraction. (A) HMGB1 band was more
intensive in MIF knockout mice than that in WT mice. (B) Histogram showed that MIF knockout bladder HMGB1 protein level is significantly
higher than that in WT mice when normalized to GAPDH. *P < 0.05.
A B C
Figure 4. Higher HMGB1 in MIF KO bladder urothelium by immunofluorescence. Urothelial HMGB1 expression was measured by
immunostaining. (A) HMGB1 was expressed in bladder urothelium in WT mice. (B) HMGB1 expression was higher in MIF knockout mice shown
by brighter staining. (C) Histogram showed that MIF knockout mice have more HMGB1 expression in bladder urothelium than that in WT mice.
*P < 0.05.
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In this study, we again observed no significant differ-
ences in awake micturition volume or frequency as a
result of intravesical treatment in either of the strains and
this agrees with our previous reports of no micturition
changes after intravesical either PAR4-AP or dsHMGB1
(Kouzoukas et al. 2015, 2016; Ma et al. 2017). There were
significant strain differences in the control groups (intrav-
esical PBS or PAR4 scramble) with MIF knockout mice
showing significant increased bladder capacity (almost
twofold). These changes are unlikely to be due to PBS or
scrambled PAR4 peptide (since PBS or PAR4 scramble
has no effect on micturition in na€ıve control MIF knock-
out mice (data not shown)). But do suggest that MIF
plays a role in bladder sensation. This last possibility
warrants further study.
We also examined if there were any basal differences in
bladder HMGB1 mRNA or protein levels between wild-
type and MIF knockout mice. Our analyses showed
increased HMGB1 mRNA and protein levels in the blad-
der of MIF knockout mice compared to wild-type mice.
Furthermore, the urothelium had higher HMGB1 protein
levels (detected by immunohistochemistry) in MIF knock-
out than in wild-type mice. It is uncertain whether
urothelial HMGB1 protein increase is due to more pro-
duction or less release in MIF knockout mice and is likely
a reflection of both effects. Nevertheless, the finding that
MIF controls HMGB1 mRNA expression, protein levels
and protein release in the bladder is a novel finding.
We previously determined that MIF is a likely factor
mediating PAR4-induced mechanical hypersensitivity
since PAR4 evoked urothelial MIF release and a MIF inhi-
bitor (ISO-1) blocked PAR4-induced abdominal mechani-
cal hypersensitivity (Kouzoukas et al. 2015). We also
showed that PAR4 activation leads to urothelial MIF
release that likely acts on MIF receptors to induce urothe-
lial HMGB1 release (Kouzoukas et al. 2016). MIF-induced
HMGB1 release is in agreement with a recent in vitro
study showed that MIF promotes HMGB1 release in
breast cancer cells (Lv et al. 2016). We also demonstrated
that intravesical dsHMGB1 (but not the thiol form) eli-
cited mechanical hypersensitivity through activation of
toll-like receptor 4 (TLR4) receptors (Ma et al. 2017).
Combining our previous findings with current results
we hypothesize that MIF directly regulates HMGB1
expression and release in the bladder to mediate bladder
pain (Fig. 5). Current results demonstrate that MIF is
upstream of HMGB1 and removing MIF (as in the case
of MIF knockout) prevents PAR4-induced abdominal
mechanical sensitivity. We previously showed reduced
protein levels of MIF and HMGB1 in the urothelium after
PAR4 activation with concomitant MIF and HMGB1
release from bladder (Kouzoukas et al. 2015, 2016). We
propose that in MIF knockout mice HMGB1 is not
released from the urothelium after PAR4-AP. Reduced
HMGB1 release from the urothelium coupled with
increased HMGB1expression in MIF knockout mice may
thus lead to protein accumulation in the urothelium.
Our current findings present evidence that MIF has a
pivotal role in visceral pain mediation in addition to its
involvement in somatic pain (Wang et al. 2010; Alexander
et al. 2012). So, we report that MIF is a major molecule
mediating HMGB1 release in bladder urothelium in the
model of PAR4-induced bladder pain that does not have
other signs of bladder inflammation. MIF and/or HMGB1
are potential novel targets in the treatment of bladder
pain independent of inflammation and may represent
new approaches to understanding and treatment of pain-
ful bladder syndrome/interstitial cystitis.
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Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Figure S1. Bladder histology after PAR4 in WT and MIF
KO mice. PAR4 or PAR4 scramble was intravesically
injected into WT and MIF knockout mice.
Figure S2. Bladder histology after dsHMGB1 in WT and
MIF KO mice. DsHMGB1 or vehicle (PBS) was intravesi-
cally injected into WT and MIF knockout mice.
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